Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic

Journal of Infectious Diseases

Volumn 202, Issue 11, 2010, Pages 1639-1648

  Chien, Yu Wen ^a   Klugman, Keith P ^a   Morens, David M ^b  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; INACTIVATED VACCINE;

ARTICLE; BACTERIAL STRAIN; DRUG EFFICACY; DRUG SYNTHESIS; FATALITY; HEMOLYTIC STREPTOCOCCUS; HUMAN; INFLUENZA VACCINATION; MILITARY SERVICE; MORTALITY; PANDEMIC INFLUENZA; PNEUMONIA; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

BACTERIAL VACCINES; HISTORY, 20TH CENTURY; HUMANS; INFLUENZA, HUMAN; MILITARY MEDICINE; MORTALITY; PANDEMICS; PNEUMONIA, BACTERIAL; REGRESSION ANALYSIS;

EID: 78649540297     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/657144     Document Type: Article

References (45)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76:105-115.
2. Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis 2008; 14:1193-1199.
3. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-970.
4. Klugman KP, Chien YW, Madhi SA. Pneumococcal pneumonia and influenza: a deadly combination. Vaccine 2009; 27(suppl 3):C9-C14.
5. Chien YW, Klugman KP, Morens DM. Bacterial pathogens and death during the 1918 influenza pandemic. N Engl J Med 2009; 361:2582-2583.
6. Eyler JM. The fog of research: influenza vaccine trials during the 1918-19 pandemic. J Hist Med Allied Sci 2009; 64:401-428.
7. McCoy GW. Status of prophylactic vaccination against influenza. JAMA 1919; 73:401-404.
8. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006; 6:303-312.
9. Elyer JM. The state of science, microbiology, and vaccines circa 1918. Public Health Rep 2010; 125(suppl 3):27-35.
10. Centers for Disease Control and Prevention. 2009-2010 influenza season: week 14 ending April 10, 2010. FluView: a weekly influenza surveillance report prepared by the Influenza Division. Atlanta, GA: Centers for Disease Control and Prevention, 2010.
11. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. http://www.cochrane-handbook.org. Updated September 2009. Accessed 20 March 2010.
12. Duval S. The trim and fill method. In: Rothstein HR, Sutton AJ, Borenstein M, eds. Publication bias in meta-analysis: prevention, assessment and adjustments. West Sussex, United Kingdom: John Wiley & Sons, 2005:128-144.
13. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006; 6:50. (Pubitemid 44662384)
14. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KGM. MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7. http://mix-for-meta-analysis.info. Accessed 20 March 2010.
15. Cadham FT. The use of a vaccine in the recent epidemic of influenza. Lancet 1919; 193:885-886.
16. Cherry TM. The value of inoculation: a statistical inquiry. In: Cumpston JHL, ed. Influenza and maritime quarantine in Australia. Vol 18. Melbourne, Australia: Australian Quarantine Service, 1919:89-113.
17. Penfold WJ. Influenza vaccine and inoculation. In: Cumpston JHL, ed. Influenza and maritime quarantine in Australia. Vol 18. Melbourne, Australia: Australian Quarantine Service, 1919:73-88.
18. Erye J, Lowe C. Autumn influenza epidemic (1918) as it affected the N.Z.E.F. in the United Kingdom. Lancet 1919; 193:553-560.
19. Leishman WB. The results of protective inoculation against influenza in the army at home, 1918-19. Lancet 1920; 195:366-368.
20. McCoy GW, Murray VB, Teeter AL. The failure of a bacterial vaccine as a prophylactic against influenza. JAMA 1918; 71:1997.
21. Minaker AJ, Irvine RS. Prophylactic use of mixed vaccine against pandemic influenza and its complications. JAMA 1919; 72:847-850.
22. Rosenow EC, Sturdivant BF. Studies in influenza and pneumonia. IV. Further results of prophylactic inoculations. JAMA 1919; 73:396-401.
23. Watters WH. Vaccines in influenza. Boston Med Surg J 1919; 181:727-731.
24. Barnes HL. The prophylactic value of Leary's vaccine. JAMA 1918; 71:1899.
25. Hinton WA, Kane ES. Use of influenza vaccine as a prophylactic: an experimental study conducted by the Massachusetts State Department of Health. J Tennessee State Med Assn 1918; 11:442-446.
26. Leary T. The use of influenza vaccine in the present epidemic. Am J Public Health 1918; 8:754-755.
27. Duval CW, Harris WH. The antigenic property of the Pfeiffer bacillus as related to its value in the prophylaxis of epidemic influenza. J Immunol 1919; 4:317-330.
28. Wadsworth AB. The results of preventive vaccination with suspensions of the influenza bacillus. Public Health J 1919; 10:309-314.
29. Ely CF, Lloyd BJ, Hitchcock CD, Nickson DH. Influenza as seen at the Puget Sound Navy Yard. JAMA 1919; 72:24-28.
30. Frost WH. The epidemiology of influenza. JAMA 1919; 73:313-318.
31. Jordan EO. Influenza studies. IV. Effect of vaccination against influenza and some other respiratory infections. J Infect Dis 1921; 28:357-366.
32. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006; 35:345-352.
33. MacCallum WG. Pathological studies in the recent epidemics of pneumonia. Trans South Surg Assoc 1919; 31:180-192.
34. Jousimies-Somer HR, Savolainen S, Ylikoski JS. Comparison of the nasal bacterial floras in two groups of healthy subjects and in patients with acute maxillary sinusitis. J Clin Microbiol 1989; 27:2736-2743.
35. Malley R, Lipsitch M, Stack A, et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001; 69:4870-4873.
36. Malley R, Morse SC, Leite LC, et al. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 2004; 72:4290-4292.
37. Centers for Disease Control and Prevention. Outbreak of group A streptococcal pneumonia among Marine Corps Recruits: California, November 1-December 20, 2002. JAMA 2003; 289:1373-1375.
38. Brundage JF, Gunzenhauser JD, Longfield JN, et al. Epidemiology and control of acute respiratory diseases with emphasis on group A beta-hemolytic streptococcus: a decade of U.S. Army experience. Pediatrics 1996; 97:964-970.
39. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811-813.
40. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1): United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1071-1074.
41. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2009; 181:72-79.
42. Gill JR, Sheng ZM, Ely SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010; 134:235-243.
43. Chowell G, Bertozzi SM, Colchero MA, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361:674-679.
44. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:1896-902.
45. Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS ONE 2009; 4:e8540.